By Fineline Cube 
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient in a Phase III clinical study evaluating BL-M07D1 for the treatment of recurrent or metastatic breast cancer with low HER2 expression.
BL-M07D1: A Promising ADC
BL-M07D1 is an antibody-drug conjugate (ADC) with best-in-class potential, demonstrating significant anti-tumor effects in clinical trials. The drug is currently the subject of 12 clinical studies, including three Phase III, three Phase II, three Phase I/II, and three Phase I trials.
Broad Indication Coverage
BL-M07D1 is being investigated for various indications, including second-line and advanced HER2-positive breast cancer, postoperative adjuvant therapy, neoadjuvant therapy, and HER2 low-expressing breast cancer. Additionally, the drug is being studied for potential applications in lung cancer, gastrointestinal tumors, urinary system tumors, and gynecological tumors.-Fineline Info & Tech